PAH (WHO Group 1) and CTEPH (WHO Group 4) are associated with endothelial dysfunction, impaired synthesis of nitric oxide (NO), and insufficient stimulation of the NO-sGC-cGMP pathway. Adempas stimulates sGC, regardless of NO level, to produce more cGMP.1
cGMP=cyclic guanosine monophosphate; CTEPH=chronic thromboembolic pulmonary hypertension; PAH=pulmonary arterial hypertension; sGC=soluble guanylate cyclase; WHO=World Health Organization
Adempas Prescribing Information. Whippany, NJ. Bayer Pharmaceuticals Inc., 2021.